Cargando…

Evaluating patient preference and satisfaction for human immunodeficiency virus therapy in France

OBJECTIVES: The objectives were 1) to elicit relative preferences for attributes of antiretroviral therapies (ART) in people living with HIV (PLWH) and 2) to explore satisfaction and adherence with current ART. PATIENTS AND METHODS: We conducted a multicenter cross-sectional study, consecutively enr...

Descripción completa

Detalles Bibliográficos
Autores principales: Brégigeon-Ronot, Sylvie, Cheret, Antoine, Cabié, André, Prazuck, Thierry, Volny-Anne, Alain, Ali, Shehzad, Bottomley, Catherine, Finkielsztejn, Laurent, Philippe, Caroline, Parienti, Jean-Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513890/
https://www.ncbi.nlm.nih.gov/pubmed/28744106
http://dx.doi.org/10.2147/PPA.S130276
_version_ 1783250731061477376
author Brégigeon-Ronot, Sylvie
Cheret, Antoine
Cabié, André
Prazuck, Thierry
Volny-Anne, Alain
Ali, Shehzad
Bottomley, Catherine
Finkielsztejn, Laurent
Philippe, Caroline
Parienti, Jean-Jacques
author_facet Brégigeon-Ronot, Sylvie
Cheret, Antoine
Cabié, André
Prazuck, Thierry
Volny-Anne, Alain
Ali, Shehzad
Bottomley, Catherine
Finkielsztejn, Laurent
Philippe, Caroline
Parienti, Jean-Jacques
author_sort Brégigeon-Ronot, Sylvie
collection PubMed
description OBJECTIVES: The objectives were 1) to elicit relative preferences for attributes of antiretroviral therapies (ART) in people living with HIV (PLWH) and 2) to explore satisfaction and adherence with current ART. PATIENTS AND METHODS: We conducted a multicenter cross-sectional study, consecutively enrolling PLWH receiving an ART. The quantitative part estimated the strength of preference for different attributes using an online discrete choice experiment (DCE). DCE data were analyzed using a mixed logit regression model. Qualitative data were collected through individual interviews. A preliminary coding framework was developed which was then further refined and applied during thematic analysis of factors influencing satisfaction and adherence. RESULTS: A total of 101 PLWH took part in the quantitative part and 31 in the qualitative part. Over 90% had an undetectable viral load. Quantitative data revealed a strong preference for a treatment with limited drug–drug interactions, diarrhea and long-term health problems (P<0.0001), and that did not need to be taken on an empty stomach (P<0.0001). Patients also preferred to avoid problems associated with treatment failure (P<0.0001) or one that left them with a higher viral load after the first weeks of treatment (P=0.044). Differences in CD4 cell count, and pills that must be taken with food were not significant drivers of treatment choice. The strength of these attributes was reflected in the qualitative data, highlighting the importance patients place on treatment efficacy, and also suggesting that some of these attributes may impact adherence. Many factors influencing adherence and satisfaction with treatment were identified, including pill size, worry about sexual transmission and impact on social life. CONCLUSION: Most of the attributes included in this survey were important to participants when choosing an ART, in particular those related to quality of life, and these should be taken into account in order to optimize adherence and satisfaction.
format Online
Article
Text
id pubmed-5513890
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-55138902017-07-25 Evaluating patient preference and satisfaction for human immunodeficiency virus therapy in France Brégigeon-Ronot, Sylvie Cheret, Antoine Cabié, André Prazuck, Thierry Volny-Anne, Alain Ali, Shehzad Bottomley, Catherine Finkielsztejn, Laurent Philippe, Caroline Parienti, Jean-Jacques Patient Prefer Adherence Original Research OBJECTIVES: The objectives were 1) to elicit relative preferences for attributes of antiretroviral therapies (ART) in people living with HIV (PLWH) and 2) to explore satisfaction and adherence with current ART. PATIENTS AND METHODS: We conducted a multicenter cross-sectional study, consecutively enrolling PLWH receiving an ART. The quantitative part estimated the strength of preference for different attributes using an online discrete choice experiment (DCE). DCE data were analyzed using a mixed logit regression model. Qualitative data were collected through individual interviews. A preliminary coding framework was developed which was then further refined and applied during thematic analysis of factors influencing satisfaction and adherence. RESULTS: A total of 101 PLWH took part in the quantitative part and 31 in the qualitative part. Over 90% had an undetectable viral load. Quantitative data revealed a strong preference for a treatment with limited drug–drug interactions, diarrhea and long-term health problems (P<0.0001), and that did not need to be taken on an empty stomach (P<0.0001). Patients also preferred to avoid problems associated with treatment failure (P<0.0001) or one that left them with a higher viral load after the first weeks of treatment (P=0.044). Differences in CD4 cell count, and pills that must be taken with food were not significant drivers of treatment choice. The strength of these attributes was reflected in the qualitative data, highlighting the importance patients place on treatment efficacy, and also suggesting that some of these attributes may impact adherence. Many factors influencing adherence and satisfaction with treatment were identified, including pill size, worry about sexual transmission and impact on social life. CONCLUSION: Most of the attributes included in this survey were important to participants when choosing an ART, in particular those related to quality of life, and these should be taken into account in order to optimize adherence and satisfaction. Dove Medical Press 2017-07-10 /pmc/articles/PMC5513890/ /pubmed/28744106 http://dx.doi.org/10.2147/PPA.S130276 Text en © 2017 Brégigeon-Ronot et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Brégigeon-Ronot, Sylvie
Cheret, Antoine
Cabié, André
Prazuck, Thierry
Volny-Anne, Alain
Ali, Shehzad
Bottomley, Catherine
Finkielsztejn, Laurent
Philippe, Caroline
Parienti, Jean-Jacques
Evaluating patient preference and satisfaction for human immunodeficiency virus therapy in France
title Evaluating patient preference and satisfaction for human immunodeficiency virus therapy in France
title_full Evaluating patient preference and satisfaction for human immunodeficiency virus therapy in France
title_fullStr Evaluating patient preference and satisfaction for human immunodeficiency virus therapy in France
title_full_unstemmed Evaluating patient preference and satisfaction for human immunodeficiency virus therapy in France
title_short Evaluating patient preference and satisfaction for human immunodeficiency virus therapy in France
title_sort evaluating patient preference and satisfaction for human immunodeficiency virus therapy in france
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513890/
https://www.ncbi.nlm.nih.gov/pubmed/28744106
http://dx.doi.org/10.2147/PPA.S130276
work_keys_str_mv AT bregigeonronotsylvie evaluatingpatientpreferenceandsatisfactionforhumanimmunodeficiencyvirustherapyinfrance
AT cheretantoine evaluatingpatientpreferenceandsatisfactionforhumanimmunodeficiencyvirustherapyinfrance
AT cabieandre evaluatingpatientpreferenceandsatisfactionforhumanimmunodeficiencyvirustherapyinfrance
AT prazuckthierry evaluatingpatientpreferenceandsatisfactionforhumanimmunodeficiencyvirustherapyinfrance
AT volnyannealain evaluatingpatientpreferenceandsatisfactionforhumanimmunodeficiencyvirustherapyinfrance
AT alishehzad evaluatingpatientpreferenceandsatisfactionforhumanimmunodeficiencyvirustherapyinfrance
AT bottomleycatherine evaluatingpatientpreferenceandsatisfactionforhumanimmunodeficiencyvirustherapyinfrance
AT finkielsztejnlaurent evaluatingpatientpreferenceandsatisfactionforhumanimmunodeficiencyvirustherapyinfrance
AT philippecaroline evaluatingpatientpreferenceandsatisfactionforhumanimmunodeficiencyvirustherapyinfrance
AT parientijeanjacques evaluatingpatientpreferenceandsatisfactionforhumanimmunodeficiencyvirustherapyinfrance